Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M15,347Revenue (TTM) $M858Net Margin (%)5.7Altman Z-Score9.6
Enterprise Value $M15,164EPS (TTM) $0.2Operating Margin %10.9Piotroski F-Score7
P/E(ttm)409Beneish M-Score-2.6Pre-tax Margin (%)5.8Higher ROA y-yY
Price/Book67.310-y EBITDA Growth Rate %--Quick Ratio4.7Cash flow > EarningsY
Price/Sales17.95-y EBITDA Growth Rate %--Current Ratio4.7Lower Leverage y-yY
Price/Free Cash Flow97.0y-y EBITDA Growth Rate %143ROA % (ttm)5.1Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)48.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M188ROIC % (ttm)127Gross Margin Increase y-yN

Gurus Latest Trades with INCY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
INCYVanguard Health Care Fund 2016-03-31 Add1.06%$63.05 - $108.45
($75)
$ 81.809%Add 68.76%16,227,748
INCYJoel Greenblatt 2016-03-31 Buy 0.04%$63.05 - $108.45
($75)
$ 81.809%New holding52,500
INCYGeorge Soros 2016-03-31 Sold Out -0.01%$63.05 - $108.45
($75)
$ 81.809%Sold Out0
INCYKen Fisher 2016-03-31 Add$63.05 - $108.45
($75)
$ 81.809%Add 0.14%14,839
INCYVanguard Health Care Fund 2015-12-31 Add0.08%$100.21 - $126.46
($111.45)
$ 81.80-27%Add 4.15%9,615,828
INCYJoel Greenblatt 2015-12-31 Sold Out -0.01%$100.21 - $126.46
($111.45)
$ 81.80-27%Sold Out0
INCYGeorge Soros 2015-12-31 Buy 0.01%$100.21 - $126.46
($111.45)
$ 81.80-27%New holding4,200
INCYKen Fisher 2015-12-31 Add$100.21 - $126.46
($111.43)
$ 81.80-27%Add 2.23%14,818
INCYVanguard Health Care Fund 2015-09-30 Reduce-0.04%$95.16 - $131.47
($112.12)
$ 81.80-27%Reduce -1.90%9,233,028
INCYJoel Greenblatt 2015-09-30 Reduce-0.01%$95.16 - $131.47
($112.12)
$ 81.80-27%Reduce -53.09%4,861
INCYKen Fisher 2015-09-30 Add$95.16 - $131.47
($112.12)
$ 81.80-27%Add 5.84%14,495
INCYVanguard Health Care Fund 2015-06-30 Reduce-0.15%$88.46 - $110.15
($103.32)
$ 81.80-21%Reduce -7.50%9,411,543
INCYJoel Greenblatt 2015-06-30 Buy 0.01%$88.46 - $110.15
($103.32)
$ 81.80-21%New holding10,363
INCYKen Fisher 2015-06-30 Reduce$88.46 - $110.15
($103.32)
$ 81.80-21%Reduce -7.90%13,695
INCYMariko Gordon 2014-12-31 Sold Out -0.05%$45.6 - $78.89
($65.73)
$ 81.8024%Sold Out0
INCYKen Fisher 2014-12-31 Add$45.6 - $78.89
($65.29)
$ 81.8025%Add 97.08%14,870
INCYVanguard Health Care Fund 2014-09-30 Add0.07%$45.35 - $56.59
($50.13)
$ 81.8063%Add 6.08%10,174,343
INCYMariko Gordon 2014-09-30 Add$45.35 - $56.59
($50.13)
$ 81.8063%Add 6.55%25,283
INCYKen Fisher 2014-09-30 Reduce$45.35 - $55.78
($50.07)
$ 81.8063%Reduce -38.28%7,545
INCYVanguard Health Care Fund 2014-06-30 Add0.68%$43.1 - $56.39
($50.98)
$ 81.8060%Add 95.66%9,591,143
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

INCY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


INCY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BAKER JULIANDirector, 10% Owner 2016-03-17Buy800,000$63.9827.85view
BAKER JULIANDirector, 10% Owner 2016-02-25Buy64,290$70.7915.55view
BAKER JULIANDirector, 10% Owner 2016-02-16Buy887,165$69.8717.07view
BAKER JULIANDirector, 10% Owner 2016-02-12Buy2,251,427$63.5328.76view
SWAIN PAULA JEVP, Human Resources 2016-01-15Sell13,531$76.966.29view
Levy Richard SEVP, Chief Drug Dev Officer 2016-01-06Sell3,937$101.86-19.69view
Siegel Eric H.EVP, General Counsel 2015-12-10Sell1,936$107.96-24.23view
Levy Richard SEVP, Chief Drug Dev Officer 2015-12-07Sell3,937$106.18-22.96view
FRIEDMAN PAUL ADirector 2015-11-18Sell225,000$113.83-28.14view
Siegel Eric H.EVP, General Counsel 2015-11-10Sell2,222$104.86-21.99view

Quarterly/Annual Reports about INCY:

News about INCY:

Articles On GuruFocus.com
Vanguard Health Care Fund Ups Stake in High-Conviction Stocks May 10 2016 
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions May 03 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
Frank Sands Acquires Stake in Netflix Feb 23 2016 
Top Insider Trades of the Past Week Feb 19 2016 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Amazon Among Ken Fisher's Best Performing Stocks Oct 19 2015 
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 

More From Other Websites
Gilead (GILD) Shares Spike After Executive Board Appointment May 25 2016
Incyte Guidance on Jakafi Sends Stock High May 24 2016
Biotech: The Next Pricing Controversy? May 23 2016
A Scarcity of Biotech Assets for Buyouts? May 20 2016
Incyte Highlights Jakafi® (ruxolitinib) and Capmatinib Abstracts to be Presented at the 2016 ASCO... May 19 2016
Incyte to Present at Upcoming Investor Conferences May 18 2016
Incyte to Present at Upcoming Investor Conferences May 18 2016
Incyte Corp. :INCY-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
INCYTE CORP Financials May 14 2016
ETF’s with exposure to Incyte Corp. : May 11, 2016 May 11 2016
ARIAD (ARIA) Q1 Loss Narrower But Revenues Disappoint (Revised) May 11 2016
ARIAD's (ARIA) Q1 Loss Narrower than Expected May 10 2016
5 things to know & an ex-bank employee's accused of stealing IDs May 10 2016
Incyte Corp. breached its 50 day moving average in a Bullish Manner : INCY-US : May 10, 2016 May 10 2016
$275M deal: Incyte to acquire biopharm firm's European operations May 09 2016
Ariad sells European operations for $140M upfront plus royalties May 09 2016
Incyte Buys European Business Hub From Ariad Pharma May 09 2016
INCYTE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 09 2016
The Zacks Analyst Blog Highlights: Horizon Pharma, Incyte, Juno Therapeutics, Halozyme Therapeutics... May 09 2016
Incyte First Quarter Financial Results Conference Call and Webcast May 09 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)